Share：
Share this content in WeChat
X
[Chinese][PDF]2581
• Clinical Article •
Preliminary study on the assessment of left atrial myocardial deformation in patients with hypertrophic cardiomyopathy using CMR technology
ZENG Fengxian  CHEN Huayan  LIN Wenjun  JIANG Jianrong  CHEN Qiqiang 

Cite this article as: ZENG F X, CHEN H Y, LIN W J, et al. Preliminary study on the assessment of left atrial myocardial deformation in patients with hypertrophic cardiomyopathy using CMR technology[J]. Chin J Magn Reson Imaging, 2024, 15(9): 74-79. DOI:10.12015/issn.1674-8034.2024.09.013.


[Abstract] Objective To explore the application value of cardiac magnetic resonance (CMR) technology in the assessment of left atrium (LA) myocardial deformation in patients with hypertrophic cardiomyopathy (HCM).Materials and Methods The clinical data of 45 HCM patients who were treated in our hospital from January 2020 to October 2023 were retrospectively analyzed. The patients underwent echocardiography and were divided into categories according to left ventricular ejection fraction (LVEF). There were 31 cases in the normal group (55%≤LVEF<70%) and 14 cases in the abnormal group (LVEF<55%). A total of 45 healthy subjects who underwent cardiac examinations in our hospital were selected as the control group. Three groups of general information and the imaging data of the CMR examination were compared between the three groups of cardiac function indicators and LA myocardial deformation indicators. Pearson correlation was used to analyze the correlation between cardiac function indicators and LA myocardial deformation indicators, and the receiver operating characteristic (ROC) curve was used. Curve analysis of the diagnostic value of myocardial deformation indicators for HCM.Results There was no statistically significant difference in gender, age, body mass index (BMI), and cardiac index among the three groups (P>0.05). The LA maximum volume (LA maximum volume, LAVmax) and LA were the smallest in the normal group and the abnormal group. The volume (LA minimum volume, LAVmin) was higher than that of the control group, the left atrial total ejection fraction (LATEF), cardiac output and LVEF were lower than those of the control group, and the LAVmax and LAVmin of the abnormal group were higher than those of the normal group. The stroke volume was lower than that in the normal group and control group (P<0.05). The storage strain and pump strain in the normal group and the abnormal group were lower than those in the control group (P<0.05). The storage strain and pump strain of the myocardial deformation indexes were negatively correlated with LAVmax and LAVmin (r=-0.605–-0.573, P<0.05). There was a positive correlation with LATEF, cardiac output, stroke volume, cardiac index and LVEF (r=0.521–0.669, P<0.05). ROC curve analysis found that the AUC of storage strain and pump strain in diagnosing HCM were 0.714 and 0.699 respectively, and the AUC of their combined diagnosis was 0.820. The sensitivity and specificity were 74.2% and 78.6% respectively (P<0.05).Conclusions CMR technology has high evaluation value in LA myocardial deformation in HCM patients. By evaluating LA myocardial deformation, it can assist in the diagnosis of HCM and also evaluate their cardiac function.
[Keywords] cardiac magnetic resonance；hypertrophic cardiomyopathy；myocardial deformation；ejection function；cardiac function；magnetic resonance imaging

ZENG Fengxian   CHEN Huayan   LIN Wenjun   JIANG Jianrong*   CHEN Qiqiang  

Department of Radiology, Mindong Hospital Affiliated to Fujian Medical University, Fu'an 355000, China

Corresponding author: JIANG J R, E-mail: zy1103290@126.com

Conflicts of interest   None.

Received  2024-02-20
Accepted  2024-08-12
DOI: 10.12015/issn.1674-8034.2024.09.013
Cite this article as: ZENG F X, CHEN H Y, LIN W J, et al. Preliminary study on the assessment of left atrial myocardial deformation in patients with hypertrophic cardiomyopathy using CMR technology[J]. Chin J Magn Reson Imaging, 2024, 15(9): 74-79. DOI:10.12015/issn.1674-8034.2024.09.013.

[1]
MARON B J, DESAI M Y, NISHIMURA R A, et al. Management of hypertrophic cardiomyopathy: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2022, 79(4): 390-414. DOI: 10.1016/j.jacc.2021.11.021.
[2]
CHOU C, CHIN M T. Genetic and molecular mechanisms of hypertrophic cardiomyopathy[J/OL]. Int J Mol Sci, 2023, 24(3): 2522 [2024-02-19]. https://pubmed.ncbi.nlm.nih.gov/36768840/. DOI: 10.3390/ijms24032522.
[3]
PATIL D, BHATT L K. Novel therapeutic avenues for hypertrophic cardiomyopathy[J]. Am J Cardiovasc Drugs, 2023, 23(6): 623-640. DOI: 10.1007/s40256-023-00609-1.
[4]
ROSSANO J W, LIN K Y. Hypertrophic cardiomyopathy: a problem at any age[J]. J Am Coll Cardiol, 2022, 79(20): 1998-2000. DOI: 10.1016/j.jacc.2022.03.356.
[5]
XU P P, ZHU X M, CHEN Y, et al. Influence of anatomic parameters of left ventricular outflow tract on hemodynamics in hypertrophic cardiomyopathy[J]. Chin J Med Imag, 2021, 29(9): 866-871. DOI: 10.3969/j.issn.1005-5185.2021.09.002.
[6]
MATTHIA E L, SETTEDUCATO M L, ELZENEINI M, et al. Circulating biomarkers in hypertrophic cardiomyopathy[J/OL]. J Am Heart Assoc, 2022, 11(23): e027618 [2024-02-19]. https://pubmed.ncbi.nlm.nih.gov/36382968/. DOI: 10.1161/JAHA.122.027618.
[7]
KITTLESON M D, CÔTÉ E. The feline cardiomyopathies: 2. hypertrophic cardiomyopathy[J]. J Feline Med Surg, 2021, 23(11): 1028-1051. DOI: 10.1177/1098612X211020162.
[8]
LIU F Y, JI Q, WANG Y L, et al. Surgical treatment for obstructive hypertrophic cardiomyopathy: a five-year single-center experience of 421 cases[J]. Chin J Surg, 2023, 61(3): 201-208. DOI: 10.3760/cma.j.cn112139-20221129-00505.
[9]
PIERONI M, CIABATTI M, SALETTI E, et al. Beyond sarcomeric hypertrophic cardiomyopathy: how to diagnose and manage phenocopies[J]. Curr Cardiol Rep, 2022, 24(11): 1567-1585. DOI: 10.1007/s11886-022-01778-2.
[10]
LIONCINO M, MONDA E, VERRILLO F, et al. Hypertrophic cardiomyopathy in RASopathies: diagnosis, clinical characteristics, prognostic implications, and management[J]. Heart Fail Clin, 2022, 18(1): 19-29. DOI: 10.1016/j.hfc.2021.07.004.
[11]
LLAMAS-ESPERÓN G A, LLAMAS-DELGADO G. Hypertrophic cardiomyopathy. Proposal for a new classification[J]. Arch Cardiol Mex, 2022, 92(3): 377-389. DOI: 10.24875/ACM.21000301.
[12]
GOSSIOS T, SAVVATIS K, ZEGKOS T, et al. Deciphering hypertrophic cardiomyopathy with electrocardiography[J]. Heart Fail Rev, 2022, 27(4): 1313-1323. DOI: 10.1007/s10741-021-10147-0.
[13]
HAUPTMEIJER R W L, LIPPERT L, CATE F E A U TEN, et al. Differentiating primary sarcomeric hypertrophic cardiomyopathy from Noonan syndrome: can the electrocardiogram be of use?[J]. Cardiol Young, 2024, 34(3): 597-603. DOI: 10.1017/S1047951123003177.
[14]
GUO L Y, MA Z L, YANG W P, et al. Identifying obstructive hypertrophic cardiomyopathy from nonobstructive hypertrophic cardiomyopathy: development and validation of a model based on electrocardiogram features[J/OL]. Glob Heart, 2023, 18(1): 40 [2024-02-19]. https://pubmed.ncbi.nlm.nih.gov/37547171/. DOI: 10.5334/gh.1250.
[15]
NAGUEH S F, PHELAN D, ABRAHAM T, et al. Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American society of echocardiography, in collaboration with the American society of nuclear cardiology, the society for cardiovascular magnetic resonance, and the society of cardiovascular computed tomography[J]. J Am Soc Echocardiogr, 2022, 35(6): 533-569. DOI: 10.1016/j.echo.2022.03.012.
[16]
SABERI S, CARDIM N, YAMANI M, et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: explorer-HCM cardiac magnetic resonance substudy analysis[J]. Circulation, 2021, 143(6): 606-608. DOI: 10.1161/CIRCULATIONAHA.120.052359.
[17]
WANG J, YANG Z G, GUO Y K, et al. The diagnostic value and research advance of magnetic resonance imaging in connective tissue disease with cardiac injury[J]. J Clin Cardiol, 2021, 37(3): 275-278. DOI: 10.13201/j.issn.1001-1439.2021.03.019.
[18]
ZHENG K C, ZHOU W, ZHU Y, et al. Evaluation of left atrial structure and function by three-dimensional echocardiography in paitents with apical hypertrophic cardiomyopathy[J]. Chin J Ultrason, 2023, 32(11): 985-994. DOI: 10.3760/cma.j.cn131148-20230613-00318.
[19]
National Cardiomyopathy Center Cardiomyopathy Specialist Alliance, China Medical Care International Exchange Promotion Association Cardiovascular Disease precision Medicine Branch "Chinese adult hypertrophic cardiomyopathy diagnosis and treatment guidelines" expert group. 2023 guideline for diagnosis and treatment of patients with hypertrophic cardiomyopathy[J]. Chin Circ J, 2023, 38(1): 1-33. DOI: 10.3969/j.issn.1000-3614.2023.01.001.
[20]
The Heart Failure Professional Committee of the National Cardiovascular Disease Expert Committee, the Heart Failure Professional Committee of the Chinese Medical Association, the Heart Failure Group of the Cardiovascular Branch of the Chinese Medical Association, et al. Chinese Guidelines for Hypertrophic Cardiomyopathy 2022[J]. Chin J Heart Failure and Cardiovascular, 2022, 6(2): 80-105. DOI: 10.3760/cma.j.cn1101460-20220805-00070.
[21]
KLINKE V, MUZZARELLI S, LAURIERS N, et al. Quality assessment of cardiovascular magnetic resonance in the setting of the European CMR registry: description and validation of standardized criteria[J/OL]. J Cardiovasc Magn Reson, 2013, 15(1): 55 [2024-02-19]. https://pubmed.ncbi.nlm.nih.gov/23787094/. DOI: 10.1186/1532-429X-15-55.
[22]
CHEN Z X, ZHANG L, NAN J, et al. Research progress of cardiac magnetic resonance in evaluating microvascular dysfunction of hypertrophic cardiomyopathy[J]. Chin J Med Imag, 2023, 31(2): 180-184. DOI: 10.3969/j.issn.1005-5185.2023.02.018.
[23]
FRIES R. Hypertrophic cardiomyopathy-advances in imaging and diagnostic strategies[J]. Vet Clin North Am Small Anim Pract, 2023, 53(6): 1325-1342. DOI: 10.1016/j.cvsm.2023.05.010.
[24]
LITT M J, ALI A Y, REZA N. Familial hypertrophic cardiomyopathy: diagnosis and management[J/OL]. Vasc Health Risk Manag, 2023, 19: 211-221 [2024-02-19]. https://pubmed.ncbi.nlm.nih.gov/37050929/. DOI: 10.2147/VHRM.S365001.
[25]
HOROWITZ B N. Hypertrophic cardiomyopathy: a species-spanning pathology[J]. J Cardiothorac Vasc Anesth, 2021, 35(9): 2815-2817. DOI: 10.1053/j.jvca.2021.03.040.
[26]
ZHANG Y, WU K H, LI Q, et al. Analysis on related factors of myocardial fibrosis in patients with hypertrophic cardiomyopathy[J]. Chin J Cardiol, 2021, 49(1): 31-36. DOI: 10.3760/cma.j.cn112148-20200609-00475.
[27]
FANG L R, XIAO J J, FAN L P, et al. Comparative study of texture features in cardiac magnetic resonance cine imaging and traditional cardiac function parameter analysis of the degree of heart failure in hypertrophic cardiomyopathy[J]. J Chongqing Med Univer, 2022, 47(6): 719-726. DOI: 10.13406/j.cnki.cyxb.003041.
[28]
KONG H H, CAO J X, TIAN J F, et al. Identification significance of cardiac magnetic resonancefeature tracking on hypertrophic cardiomyopathy and mild hypertensive heart disease[J]. J Clin Radiol, 2022, 41(9): 1660-1664.
[29]
DAI Y Q, XIE W H, HONG H S. Progress in end-stage phase of hypertrophic cardiomyopathy[J]. Chin J Heart Fail Cardiomyopathy, 2021, 5(1): 67-73. DOI: 10.3760/cma.j.cn101460-20201221-00126.
[30]
ZHANG M, SUN X L, WU G X, et al. Clinical and genetic characteristics of different types of non-obstructive hypertrophic cardiomyopathy[J]. Chin J Cardiol, 2021, 49(6): 593-600. DOI: 10.3760/cma.j.cn112148-20210118-00056.
[31]
PAN C K, ZHAO B W, ZHANG X X, et al. Three-dimensional echocardiographic assessment of left ventricular volume in different heart diseases using a fully automated quantification software[J]. World J Clin Cases, 2022, 10(13): 4050-4063. DOI: 10.12998/wjcc.v10.i13.4050.
[32]
XIA R, TAO L, LIAO J C, et al. The relationship of left ventricular myocardial fibrosis and left atrial function parameters of patients with hypertensive heart disease[J]. Chin J Magn Reson Imag, 2022, 13(12): 20-25. DOI: 10.12015/issn.1674-8034.2022.12.004.
[33]
WANG W, BAI H, ZHOU J L, et al. Evaluating changes of left ventricular diastolic fluid by vector flow mapping in patients with hypertrophic cardiomyopathy[J]. Chin J Ultrasound Med, 2023, 39(1): 30-34. DOI: 10.3969/j.issn.1002-0101.2023.01.008.
[34]
CHEN Z X, LI C M, LI Y J, et al. Layer-specific strain echocardiography may reflect regional myocardial impairment in patients with hypertrophic cardiomyopathy[J/OL]. Cardiovasc Ultrasound, 2021, 19(1): 15 [2024-02-19]. https://pubmed.ncbi.nlm.nih.gov/33658038/. DOI: 10.1186/s12947-021-00244-3.
[35]
BOBAN M. Editorial for "left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: the utility of myocardial strain based on cardiac MR tissue tracking"[J]. J Magn Reson Imaging, 2021, 53(2): 552-553. DOI: 10.1002/jmri.27336.
[36]
Hu M Y, Gong L G, Yu S S. Comparative study of MR tissue tracking technology on left and right ventricular myocardial strain in hypertensive heart disease[J]. J Clin Radio, 2022, 41(10): 1883-1888. DOI: 10.13437/j.cnki.jcr.2022.10.033.
[37]
ZHAO Q Q, CUI C Y, LI Y N, et al. Evaluation of myocardial work in patients with hypertrophic cardiomyopathy and hypertensive left ventricular hypertrophy based on non-invasive pressure-strain loops[J/OL]. Front Cardiovasc Med, 2022, 9: 767875 [2024-02-19]. https://pubmed.ncbi.nlm.nih.gov/35958393/. DOI: 10.3389/fcvm.2022.767875.

PREV Imaging evaluation of long-term over-drinkers myocardial injury by cardiac magnetic resonance feature tracking techniques
NEXT Correlation of full-volume IVIM quantitative parameters with neurovascular invasion, MSI status, and Ki-67 index in rectal adenocarcinoma
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn